Amphastar Pharmaceuticals (AMPH) EBIT: 2013-2025
Historic EBIT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $25.3 million.
- Amphastar Pharmaceuticals' EBIT fell 55.62% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.9 million, marking a year-over-year decrease of 30.02%. This contributed to the annual value of $205.4 million for FY2024, which is 4.28% up from last year.
- According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' EBIT is $25.3 million, which was down 39.98% from $42.2 million recorded in Q2 2025.
- In the past 5 years, Amphastar Pharmaceuticals' EBIT registered a high of $72.7 million during Q3 2023, and its lowest value of $10.3 million during Q1 2021.
- Over the past 3 years, Amphastar Pharmaceuticals' median EBIT value was $45.1 million (recorded in 2024), while the average stood at $46.1 million.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' EBIT surged by 742.38% in 2021, and later crashed by 55.62% in 2025.
- Amphastar Pharmaceuticals' EBIT (Quarterly) stood at $24.3 million in 2021, then soared by 56.00% to $37.8 million in 2022, then spiked by 42.68% to $54.0 million in 2023, then decreased by 16.37% to $45.1 million in 2024, then tumbled by 55.62% to $25.3 million in 2025.
- Its EBIT stands at $25.3 million for Q3 2025, versus $42.2 million for Q2 2025 and $37.3 million for Q1 2025.